121 related articles for article (PubMed ID: 15610448)
1. Impact of gemcitabine on the treatment of metastatic pancreatic cancer.
Ishii H; Furuse J; Nagase M; Yoshino M
J Gastroenterol Hepatol; 2005 Jan; 20(1):62-6. PubMed ID: 15610448
[TBL] [Abstract][Full Text] [Related]
2. Treatment cost of pancreatic cancer in Japan: analysis of the difference after the introduction of gemcitabine.
Ishii H; Furuse J; Kinoshita T; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Nakachi K; Suzuki E; Yoshino M
Jpn J Clin Oncol; 2005 Sep; 35(9):526-30. PubMed ID: 16120621
[TBL] [Abstract][Full Text] [Related]
3. Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan.
Nakai Y; Isayama H; Sasaki T; Sasahira N; Kogure H; Hirano K; Tsujino T; Ijichi H; Tateishi K; Tada M; Omata M; Koike K
Jpn J Clin Oncol; 2010 Aug; 40(8):774-80. PubMed ID: 20462979
[TBL] [Abstract][Full Text] [Related]
4. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.
Brasiūnas V; Brasiūniene B; Juozaityte E; Barauskas G
Medicina (Kaunas); 2004; 40(11):1074-80. PubMed ID: 15547308
[TBL] [Abstract][Full Text] [Related]
6. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.
Altwegg R; Ychou M; Guillaumon V; Thezenas S; Senesse P; Flori N; Mazard T; Caillo L; Faure S; Samalin E; Assenat E
World J Gastroenterol; 2012 Mar; 18(12):1357-64. PubMed ID: 22493549
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
Park JK; Ryu JK; Lee JK; Yoon WJ; Lee SH; Kim YT; Yoon YB
Pancreas; 2006 Nov; 33(4):397-402. PubMed ID: 17079946
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors].
An SG; Kim DU; Song GA; Jang AL
Korean J Gastroenterol; 2014 Dec; 64(6):356-63. PubMed ID: 25530587
[TBL] [Abstract][Full Text] [Related]
10. Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients.
Kuroda T; Kumagi T; Yokota T; Seike H; Nishiyama M; Imai Y; Inada N; Shibata N; Imamine S; Okada S; Koizumi M; Yamanishi H; Azemoto N; Miyaike J; Tanaka Y; Tatsukawa H; Utsunomiya H; Ohno Y; Miyake T; Hirooka M; Furukawa S; Abe M; Ikeda Y; Matsuura B; Hiasa Y; Onji M;
BMC Gastroenterol; 2013 Aug; 13():134. PubMed ID: 24256464
[TBL] [Abstract][Full Text] [Related]
11. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Gourgou-Bourgade S; Bascoul-Mollevi C; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Boige V; Bérille J; Conroy T
J Clin Oncol; 2013 Jan; 31(1):23-9. PubMed ID: 23213101
[TBL] [Abstract][Full Text] [Related]
12. Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma.
Hong GB; Zhou JX; Sun HB; Li CY; Song LQ
Asian Pac J Cancer Prev; 2012; 13(6):2669-73. PubMed ID: 22938439
[TBL] [Abstract][Full Text] [Related]
13. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
[TBL] [Abstract][Full Text] [Related]
14. Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine.
Sawaki A; Kanemitsu Y; Mizuno N; Takahashi K; Nakamura T; Ioka T; Tanaka S; Nakaizumi A; Salem AA; Ueda R; Yamao K
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1292-7. PubMed ID: 18700899
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine therapy in patients with advanced pancreatic cancer.
Min YJ; Joo KR; Park NH; Yun TK; Nah YW; Nam CW; Park JH
Korean J Intern Med; 2002 Dec; 17(4):259-62. PubMed ID: 12647642
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of gemcitabine therapy for recurrent or metastatic pancreatic cancer].
Moriwaki T; Hyodo I; Nishina T; Nasu J; Hidaka S; Kajiwara T; Tsuzuki T; Hirao K; Tsubouchi E; Yamauchi Y; Hirasaki S; Masumoto T; Tanada M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1373-6. PubMed ID: 15446559
[TBL] [Abstract][Full Text] [Related]
18. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival.
Takahashi H; Ohigashi H; Ishikawa O; Eguchi H; Gotoh K; Yamada T; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K; Yano M
Ann Surg; 2010 Mar; 251(3):461-9. PubMed ID: 20134315
[TBL] [Abstract][Full Text] [Related]
19. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract][Full Text] [Related]
20. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.
Goulart BH; Clark JW; Lauwers GY; Ryan DP; Grenon N; Muzikansky A; Zhu AX
J Hematol Oncol; 2009 Mar; 2():13. PubMed ID: 19291303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]